Advances in development of new treatment for leishmaniasis

BioMed Research International

Volumn 2015, Issue , 2015, Pages

  De Menezes, Juliana Perrone Bezerra ^a   Guedes, Carlos Eduardo Sampaio ^a   De Oliveira Almeida Petersen, Antônio Luis ^a   Fraga, Deborah Bittencourt Mothé ^a   Veras, Patrícia Sampaio Tavares ^a  

^a INSTITUTO OSWALDO CRUZ   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; HEAT SHOCK PROTEIN 90;

CHEMOTHERAPY; DRUG IDENTIFICATION; DRUG TARGETING; HIGH THROUGHPUT SCREENING; HUMAN; INTERVENTION STUDY; LEISHMANIA; LEISHMANIASIS; NONHUMAN; REVIEW; DRUG DELIVERY SYSTEM; DRUG EFFECTS; GENETICS; MOLECULARLY TARGETED THERAPY; PARASITOLOGY; PATHOGENICITY; PATHOPHYSIOLOGY;

PROTOZOA;

DRUG DELIVERY SYSTEMS; HUMANS; LEISHMANIA; LEISHMANIASIS; MOLECULAR TARGETED THERAPY;

EID: 84930651406     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2015/815023     Document Type: Review

References (139)

1. WHO, Control of the Leishmaniases, WHO Technical Report Series, WHO, Geneva, Switzerland, 2010.
2. G. Grimaldi Jr. and R. B. Tesh, "Leishmaniases of the New World: current concepts and implications for future research", Clinical Microbiology Reviews, vol. 6, no. 3, pp. 230-250, 1993.
3. H. W. Murray, J. D. Berman, C. R. Davies, and N. G. Saravia, "Advances in leishmaniasis", The Lancet, vol. 366, no. 9496, pp. 1561-1577, 2005.
4. P. Desjeux, "Leishmaniasis: current situation and new perspectives", Comparative Immunology, Microbiology and Infectious Diseases, vol. 27, no. 5, pp. 305-318, 2004.
5. R. W. Ashford, "The leishmaniases as emerging and reemerging zoonoses", International Journal for Parasitology, vol. 30, no. 12-13, pp. 1269-1281, 2000.
6. P. Trouiller, P. Olliaro, E. Torreele, J. Orbinski, R. Laing, and N. Ford, "Drug development for neglected diseases: a deficient market and a public-health policy failure", The Lancet, vol. 359, no. 9324, pp. 2188-2194, 2002.
7. A. R. Renslo and J. H. McKerrow, "Drug discovery and development for neglected parasitic diseases", Nature Chemical Biology, vol. 2, no. 12, pp. 701-710, 2006.
8. A. K. Cruz, J. S. De Toledo, M. Falade et al., "Current treatment and drug discovery against Leishmania spp. and Plasmodium spp.: a review", Current Drug Targets, vol. 10, no. 3, pp. 178-192, 2009.
9. V. S. Amato, F. F. Tuon, H. A. Bacha, V. A. Neto, and A. C. Nicodemo, "Mucosal leishmaniasis: current scenario and prospects for treatment", Acta Tropica, vol. 105, no. 1, pp. 1-9, 2008.
10. J. Van Griensven, M. Balasegaram, F. Meheus, J. Alvar, L. Lynen, and M. Boelaert, "Combination therapy for visceral leishmaniasis", The Lancet Infectious Diseases, vol. 10, no. 3, pp. 184-194, 2010.
11. P. L. Olliaro and A. D. M. Bryceson, "Practical progress and new drugs for changing patterns of leishmaniasis", Parasitology Today, vol. 9, no. 9, pp. 323-328, 1993.
12. J. D. Berman, "Human leishmaniasis: clinical, diagnostic, and chemotherapeutic developments in the last 10 years", Clinical Infectious Diseases, vol. 24, no. 4, pp. 684-703, 1997.
13. L. H. Freitas-Junior, E. Chatelain, H. A. Kim, and J. L. Siqueira-Neto, "Visceral leishmaniasis treatment: what do we have, what do we need and how to deliver it?" International Journal for Parasitology: Drugs and Drug Resistance, vol. 2, pp. 11-19, 2012.
14. T. S. Tiuman, A. O. Santos, T. Ueda-Nakamura, B. P. D. Filho, and C. V. Nakamura, "Recent advances in leishmaniasis treatment", International Journal of Infectious Diseases, vol. 15, no. 8, pp. e525-e532, 2011.
15. S. L. Croft and V. Yardley, "Chemotherapy of leishmaniasis", Current Pharmaceutical Design, vol. 8, no. 4, pp. 319-342, 2002.
16. S. L. Croft and G. H. Coombs, "Leishmaniasis-current chemotherapy and recent advances in the search for novel drugs", Trends in Parasitology, vol. 19, no. 11, pp. 502-508, 2003.
17. Y. Melaku, S. M. Collin, K. Keus, F. Gatluak, K. Ritmeijer, and R. N. Davidson, "Treatment of kala-azar in southern Sudan using a 17-day regimen of sodium stibogluconate combined with paromomycin: a retrospective comparison with 30-day sodium stibogluconate monotherapy", American Journal of Tropical Medicine and Hygiene, vol. 77, no. 1, pp. 89-94, 2007.
18. C. P. Thakur, S. Narayan, and A. Ranjan, "Epidemiological, clinical & pharmacological study of antimony-resistant visceral leishmaniasis in Bihar, India", Indian Journal of Medical Research, vol. 120, no. 3, pp. 166-172, 2004.
19. F. Frézard, C. Demicheli, and R. R. Ribeiro, "Pentavalent antimonials: new perspectives for old drugs", Molecules, vol. 14, no. 7, pp. 2317-2336, 2009.
20. S. Sundar, "Drug resistance in Indian visceral leishmaniasis", Tropical Medicine and International Health, vol. 6, no. 11, pp. 849-854, 2001.
21. S. L. Croft, K. Seifert, and V. Yardley, "Current scenario of drug development for leishmaniasis", Indian Journal of Medical Research, vol. 123, no. 3, pp. 399-410, 2006.
22. S. L. Croft and P. Olliaro, "Leishmaniasis chemotherapy-challenges and opportunities", Clinical Microbiology and Infection, vol. 17, no. 10, pp. 1478-1483, 2011.
23. F. Meheus, M. Balasegaram, P. Olliaro et al., "Cost-effectiveness analysis of combination therapies for visceral leishmaniasis in the Indian subcontinent", PLoS Neglected Tropical Diseases, vol. 4, no. 9, Article e818, 2010.
24. N. Singh, M. Kumar, and R. K. Singh, "Leishmaniasis: current status of available drugs and new potential drug targets", Asian Pacific Journal of Tropical Medicine, vol. 5, no. 6, pp. 485-497, 2012.
25. P. G. Bray, M. P. Barrett, S. A. Ward, and H. P. De Koning, "Pentamidine uptake and resistance in pathogenic protozoa: past, present and future", Trends in Parasitology, vol. 19, no. 5, pp. 232-239, 2003.
26. K. Jain and N. K. Jain, "Novel therapeutic strategies for treatment of visceral leishmaniasis", Drug Discovery Today, vol. 18, no. 23-24, pp. 1272-1281, 2013.
27. D. Fong, M. M.-Y. Chan, R. Rodriguez, L. J. Gately, J. D. Berman, and M. Grogl, "Paromomycin resistance in Leishmania tropica: lackof correlationwithmutation in the small subunit ribosomal RNA gene", American Journal of TropicalMedicine and Hygiene, vol. 51, no. 6, pp. 758-766, 1994.
28. A. Jhingran, B. Chawla, S. Saxena, M. P. Barrett, and R. Madhubala, "Paromomycin: uptake and resistance in Leishmania donovani", Molecular and Biochemical Parasitology, vol. 164, no. 2, pp. 111-117, 2009.
29. S. Hendrickx, R. A. I. Da Luz, V. Bhandari et al., "Experimental induction of paromomycin resistance in antimony-resistant strains of L. donovani: outcome dependent on in vitro selection protocol", PLoSNeglected Tropical Diseases, vol. 6, no. 5, Article ID e1664, 2012.
30. H. Sindermann, S. L. Croft, K. R. Engel et al., "Miltefosine (Impavido): the first oral treatment against leishmaniasis", Medical Microbiology and Immunology, vol. 193, no. 4, pp. 173-180, 2004.
31. V. Yeo-Gamarra, C. Rodriguez-Ulhoa, C. Diaz-Velez et al., "Sa 1914 sequential versus triple standard therapy for Helicobacter pylori eradication", Gastroenterology, vol. 144, no. 5, p. S-333, 2013.
32. S. Sundar and P. L. Olliaro, "Miltefosine in the treatment of leishmaniasis: clinical evidence for informed clinical risk management", Therapeutics and Clinical Risk Management, vol. 3, no. 5, pp. 733-740, 2007.
33. E. Kandil, "Treatment of cutaneous leishmaniasis with trimethoprim sulfamethoxazole combination", Dermatologica, vol. 146, no. 5, pp. 303-309, 1973.
34. Z. Even-Paz, L. Weinrauch, R. Livshin, J. El-On, and C. L. Greenblatt, "Rifampicin treatment of cutaneous leishmaniasis", International Journal of Dermatology, vol. 21, no. 2, pp. 110-112, 1982.
35. M. Z. Hossain, "Combination therapy (momomycine and methyluracil) in leishmaniasis cutis", International Journal of Dermatology, vol. 27, no. 10, pp. 720-722, 1988.
36. P. D. Marsden, C. C. Cuba, A. C. Barreto, R. N. Sampaio, and R. A. A. Rocha, "Nifurtimox in the treatment of South American leishmaniasis", Transactions of the Royal Society of Tropical Medicine and Hygiene, vol. 73, no. 4, pp. 391-394, 1979.
37. A. Masmoudi, A. Dammak, H. Chaaben, N. Maalej, F. Akrout, and H. Turki, "Doxycycline for the treatment of cutaneous leishmaniasis", Dermatology Online Journal, vol. 14, no. 8, p. 22, 2008.
38. D. C. Miguel, J. K. U. Yokoyama-Yasunaka, and S. R. B. Uliana, "Tamoxifen is effective in the treatment of Leishmania amazonensis infections in mice", PLoS Neglected Tropical Diseases, vol. 2, no. 6, Article e249, 2008.
39. D. C. Miguel, R. C. Zauli-Nascimento, J. K. U. Yokoyama-Yasunaka, S. Katz, C. L. Barbiéri, and S. R. B. Uliana, "Tamoxifen as a potential antileishmanial agent: efficacy in the treatment of Leishmania braziliensisand Leishmania chagasi infections", Journal of Antimicrobial Chemotherapy, vol. 63, no. 2, pp. 365-368, 2009.
40. J. Alvar, S. Croft, and P. Olliaro, "Chemotherapy in the treatment and control of leishmaniasis", Advances in Parasitology, vol. 61, pp. 223-274, 2006.
41. F. Astelbauer and J. Walochnik, "Antiprotozoal compounds: state of the art and new developments", International Journal of Antimicrobial Agents, vol. 38, no. 2, pp. 118-124, 2011.
42. D. C. Miguel, J. K. U. Yokoyama-Yasunaka, W. K. Andreoli, R. A. Mortara, and S. R. B. Uliana, "Tamoxifen is effective against Leishmania and induces a rapid alkalinization of parasitophorous vacuoles harbouring Leishmania (Leishmania) amazonensis amastigotes", Journal of Antimicrobial Chemotherapy, vol. 60, no. 3, pp. 526-534, 2007.
43. J. V. Richard and K. A. Werbovetz, "New antileishmanial candidates and lead compounds", Current Opinion in Chemical Biology, vol. 14, no. 4, pp. 447-455, 2010.
44. S. Wyllie, S. Patterson, L. Stojanovski et al., "The antitrypanosome drug fexinidazole shows potential for treating visceral leishmaniasis", Science Translational Medicine, vol. 4, no. 119, Article ID 119re1, 2012.
45. P. Minodier and P. Parola, "Cutaneous leishmaniasis treatment", TravelMedicine and Infectious Disease, vol. 5, no. 3, pp. 150-158, 2007.
46. I. Arevalo, B. Ward, R. Miller et al., "Successful treatment of drug-resistant cutaneous leishmaniasis in humans by use of imiquimod, an immunomodulator", Clinical InfectiousDiseases, vol. 33, no. 11, pp. 1847-1851, 2001.
47. C. Miranda-Verastegui, G. Tulliano, T. W. Gyorkos et al., "Firstline therapy for human cutaneous leishmaniasis in Peru using the TLR7 agonist imiquimod in combination with pentavalent antimony", PLoS Neglected Tropical Diseases, vol. 3, no. 7, Article e491, 2009.
48. S. Sundar, P. K. Sinha, M. Rai et al., "Comparisonof short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trial", The Lancet, vol. 377, no. 9764, pp. 477-486, 2011.
49. K. Seifert and S. L. Croft, "In vitro and in vivo interactions between miltefosine and other antileishmanial drugs", Antimicrobial Agents and Chemotherapy, vol. 50, no. 1, pp. 73-79, 2006.
50. S. Bimal, S. Sinha, S. K. Singh et al., "Leishmania donovani: CD2 biased immune response skews the SAG mediated therapy for a predominant Th1 response in experimental infection", Experimental Parasitology, vol. 131, no. 3, pp. 274-282, 2012.
51. N. Shakya, S. A. Sane, P. Vishwakarma, and S. Gupta, "Enhancement in therapeutic efficacy of miltefosine in combination with synthetic bacterial lipopeptide, Pam3Cys against experimental Visceral Leishmaniasis", Experimental Parasitology, vol. 131, no. 3, pp. 377-382, 2012.
52. M. Hamidi, A. Azadi, and P. Rafiei, "Hydrogel nanoparticles in drug delivery", Advanced Drug Delivery Reviews, vol. 60, no. 15, pp. 1638-1649, 2008.
53. L. Brannon-Peppas, "Controlled release of beta-estradiol from biodegradable microparticles within a silicone matrix", Journal of Biomaterials Science (Polymer Edition), vol. 5, no. 4, pp. 339-351, 1994.
54. M. Petitti, M. Vanni, and A. A. Barresi, "Controlled release of drug encapsulated as a solid core: theoretical model and sensitivity analysis", Chemical Engineering Research and Design, vol. 86, no. 11, pp. 1294-1300, 2008.
55. M. Solomon, F. Pavlotzky, A. Barzilai, and E. Schwartz, "Liposomal amphotericin B in comparison to sodium stibogluconate for Leishmania braziliensis cutaneous leishmaniasis in travelers", Journal of the American Academy of Dermatology, vol. 68, no. 2, pp. 284-289, 2013.
56. M. Solomon, S. Baum, A. Barzilai, A. Scope, H. Trau, and E. Schwartz, "Liposomal amphotericin B in comparison to sodium stibogluconate for cutaneous infection due to Leishmania braziliensis", Journal of the American Academy of Dermatology, vol. 56, no. 4, pp. 612-616, 2007.
57. S. Burza, R. Mahajan, P. K. Sinha et al., "Visceral leishmaniasis and HIV co-infection in Bihar, India: long-term effectiveness and treatment outcomes with liposomal amphotericin B (AmBisome)", PLoS Neglected Tropical Diseases, vol. 8, no. 8, Article ID e3053, 2014.
58. K. Ritmeijer, R. Ter Horst, S. Chane et al., "Limited effectiveness of high-dose liposomal amphotericin B (AmBisome) for treatment of visceral leishmaniasis in an ethiopian population with high HIV prevalence", Clinical Infectious Diseases, vol. 53, no. 12, pp. e152-e158, 2011.
59. J. Roychoudhury, R. Sinha, and N. Ali, "Therapy with sodium stibogluconate in stearylamine-bearing liposomes confers cure against SSG-resistant Leishmania donovani in BALB/c mice", PLoS ONE, vol. 6, no. 3, Article ID e17376, 2011.
60. M. T. Shio, M. Paquet, C. Martel et al., "Drug delivery by tattooing to treat cutaneous leishmaniasis", Scientific Reports, vol. 4, Article 4156, 2014.
61. V. K. Prajapati, K. Awasthi, S. Gautam et al., "Targeted killing of Leishmania donovani in vivo and in vitro with amphotericin B attached to functionalized carbon nanotubes", Journal of Antimicrobial Chemotherapy, vol. 66, no. 4, pp. 874-879, 2011.
62. P. Saudagar and V. K. Dubey, "Carbon nanotube based betulin formulation shows better efficacy against Leishmania parasite", Parasitology International, vol. 63, no. 6, pp. 772-776, 2014.
63. T. G. Ribeiro, M. A. Chávez-Fumagall, D. G. Valadares et al., "Novel targeting using nanoparticles: an approach to the development of an effective anti-leishmanial drug-delivery system", International Journal of Nanomedicine, vol. 9, no. 1, pp. 877-890, 2014.
64. E. R. Sharlow, D. Close, T. Shun et al., "Identification of potent chemotypes targeting Leishmania major using a highthroughput, low-stringency, computationally enhanced, small molecule screen", PLoS Neglected Tropical Diseases, vol. 3, no. 11, Article e540, 2009.
65. J. L. Siqueira-Neto, O.-R. Song, H. Oh et al., "Antileishmanial high-throughput drug screening reveals drug candidates with new scaffolds", PLoS Neglected Tropical Diseases, vol. 4, no. 5, Article e675, 2010.
66. Y. Osorio, B. L. Travi, A. R. Renslo, A. G. Peniche, and P. C. Melby, "Identification of small molecule lead compounds for visceral leishmaniasis using a novel ex vivo splenic explant model system", PLoS Neglected Tropical Diseases, vol. 5, no. 2, Article e962, 2011.
67. S. Kumari, A. Kumar, M. Samant, N. Singh, and A. Dube, "Discovery of novel vaccine candidates and drug targets against visceral leishmaniasis using proteomics and transcriptomics", Current Drug Targets, vol. 9, no. 11, pp. 938-947, 2008.
68. D. Paape and T. Aebischer, "Contribution of proteomics of Leishmania spp. to the understanding of differentiation, drug resistance mechanisms, vaccine and drug development", Journal of Proteomics, vol. 74, no. 9, pp. 1614-1624, 2011.
69. J. B. Carnielli, H. M. De Andrade, S. F. Pires et al., "Proteomic analysis of the soluble proteomes of miltefosine-sensitive and -resistant Leishmania infantum chagasi isolates obtained from Brazilian patients with different treatment outcomes", Journal of Proteomics, vol. 108, pp. 198-208, 2014.
70. M.-C. Brotherton, S. Bourassa, D. Légaré, G. G. Poirier, A. Droit, and M. Ouellette, "Quantitative proteomic analysis of amphotericin B resistance in Leishmania infantum", International Journal for Parasitology: Drugs and Drug Resistance, vol. 4, no. 2, pp. 126-132, 2014.
71. R. F. S. Menna-Barreto, D. G. Beghini, A. T. S. Ferreira, A. V. Pinto, S. L. De Castro, and J. Perales, "A proteomic analysis of themechanism of action of naphthoimidazoles in Trypanosoma cruzi epimastigotes in vitro", Journal of Proteomics, vol. 73, no. 12, pp. 2306-2315, 2010.
72. A. Trochine, G. Alvarez, S. Corre et al., "Trypanosoma cruzi chemical proteomics using immobilized benznidazole", Experimental Parasitology, vol. 140, no. 1, pp. 33-38, 2014.
73. L. Mercer, T. Bowling, J. Perales et al., "2, 4-Diaminopyrimidines as potent inhibitors of trypanosoma brucei and identification of molecular targets by a chemical proteomics approach", PLoS Neglected Tropical Diseases, vol. 5, no. 2, Article e956, 2011.
74. C. Doliwa, D. Xia, S. Escotte-Binet et al., "Identification of differentially expressed proteins in sulfadiazine resistant and sensitive strains of Toxoplasma gondii using difference-gel electrophoresis (DIGE)", International Journal for Parasitology: Drugs and Drug Resistance, vol. 3, pp. 35-44, 2013.
75. A. Pantaleo, E. Ferru, R. Vono et al., "New antimalarial indolone-N-oxides, generating radical species, destabilize the host cell membrane at early stages of Plasmodium falciparum growth: role of band 3 tyrosine phosphorylation", Free Radical Biology and Medicine, vol. 52, no. 2, pp. 527-536, 2012.
76. S. Briolant, L. Almeras, M. Belghazi et al., "Plasmodium falciparum proteome changes in response to doxycycline treatment", Malaria Journal, vol. 9, no. 1, Article 141, 2010.
77. P. Nahid, E. Bliven-Sizemore, L. G. Jarlsberg et al., "Aptamerbased proteomic signature of intensive phase treatment response in pulmonary tuberculosis", Tuberculosis, vol. 94, no. 3, pp. 187-196, 2014.
78. S. Nabu, R. Lawung, P. Isarankura-Na-Ayudhya, C. Isarankura-Na-Ayudhya, S. Roytrakul, and V. Prachayasittikul, "Reference map and comparative proteomic analysis of Neisseria gonorrhoeae displaying high resistance against spectinomycin", Journal of MedicalMicrobiology, vol. 63, no. 3, pp. 371-385, 2014.
79. B. A. Diep, Q. Phung, S. Date et al., "Identifying potential therapeutic targets of methicillin-resistant staphylococcus aureus through in vivo proteomic analysis", Journal of Infectious Diseases, vol. 209, no. 10, pp. 1533-1541, 2014.
80. c", Journal of Proteomics, vol. 103, pp. 103-120, 2014.
81. V. N. Schreier, L. Petho, E. Orbán et al., "Protein expression profile of HT-29 human colon cancer cells after treatment with a cytotoxic daunorubicin-GnRH-III derivative bioconjugate", PLoS ONE, vol. 9, no. 4, Article ID e94041, 2014.
82. A. Ilyas, Z. Hashim, N. Naeem, K. Haneef, and S. Zarina, "The effect of alendronate on proteome of hepatocellular carcinoma cell lines", International Journal of Proteomics, vol. 2014, Article ID 532953, 9 pages, 2014.
83. E. Fischer and U. Sauer, "Large-scale in vivo flux analysis shows rigidity and suboptimal performance of Bacillus subtilis metabolism", Nature Genetics, vol. 37, no. 6, pp. 636-640, 2005.
84. M. K. Hellerstein, "Acritique of themolecular target-based drug discovery paradigm based on principles of metabolic control: advantages of pathway-based discovery", Metabolic Engineering, vol. 10, no. 1, pp. 1-9, 2008.
85. G. Duyk, "Attrition and translation", Science, vol. 302, no. 5645, pp. 603-605, 2003.
86. J. P. B. Menezes, T. F. Almeida, A. L. O. A. Petersen et al., "Proteomic analysis reveals differentially expressed proteins in macrophages infected with Leishmania amazonensis or Leishmania major", Microbes and Infection, vol. 15, no. 8-9, pp. 579-591, 2013.
87. C. M. Probst, R. A. Silva, J. P. B. Menezes et al., "A comparison of two distinct murine macrophage gene expression profiles in response to Leishmania amazonensis infection", BMC Microbiology, vol. 12, Article 22, 2012.
88. J. Osorio Y Fortéa, E. De La Llave, B. Regnault et al., "Transcriptional signatures of BALB/c mouse macrophages housing multiplying Leishmania amazonensis amastigotes", BMC Genomics, vol. 10, Article 119, 2009.
89. F. McNicoll, J. Drummelsmith, M. Müller et al., "A combined proteomic and transcriptomic approach to the study of stage differentiation in Leishmania infantum", Proteomics, vol. 6, no. 12, pp. 3567-3581, 2006.
90. N. S. Akopyants, S. W. Clifton, J. Martin et al., "A survey of the Leishmania major Friedlin strain V1 genome by shotgun sequencing: a resource for DNA microarrays and expression profiling", Molecular and Biochemical Parasitology, vol. 113, no. 2, pp. 337-340, 2001.
91. Y. El Fakhry, M. Ouellette, and B. Papadopoulou, "A proteomic approach to identify developmentally regulated proteins in Leishmania infantum", Proteomics, vol. 2, no. 8, pp. 1007-1017, 2002.
92. N. S. Akopyants, R. S. Matlib, E. N. Bukanova et al., "Expression profiling using random genomic DNA microarrays identifies differentially expressed genes associated with threemajor developmental stages of the protozoan parasite Leishmania major", Molecular and Biochemical Parasitology, vol. 136, no. 1, pp. 71-86, 2004.
93. L. R. V. Antonelli, W. O. Dutra, R. P. Almeida, O. Bacellar, and K. J. Gollob, "Antigen specific correlations of cellular immune responses in human leishmaniasis suggests mechanisms for immunoregulation", Clinical and Experimental Immunology, vol. 136, no. 2, pp. 341-348, 2004.
94. R. C. Duncan, P. Salotra, N. Goyal, N. S. Akopyants, S. M. Beverley, and H. L. Nakhasi, "The application of gene expression microarray technology to kinetoplastid research", Current Molecular Medicine, vol. 4, no. 6, pp. 611-621, 2004.
95. P. G. Nugent, S. A. Karsani, R. Wait, J. Tempero, and D. F. Smith, "Proteomic analysis of Leishmania mexicana differentiation", Molecular and Biochemical Parasitology, vol. 136, no. 1, pp. 51-62, 2004.
96. A. Saxena, T. Lahav, N. Holland et al., "Analysis of the Leishmania donovani transcriptome reveals an ordered progression of transient and permanent changes in gene expression during differentiation", Molecular and Biochemical Parasitology, vol. 152, no. 1, pp. 53-65, 2007.
97. M. Thiel and I. Bruchhaus, "Comparative proteome analysis of Leishmania donovani at different stages of transformation from promastigotes to amastigotes", Medical Microbiology and Immunology, vol. 190, no. 1-2, pp. 33-36, 2001.
98. J. Drummelsmith, V. Brochu, I. Girard, N. Messier, and M. Ouellette, "Proteome mapping of the protozoan parasite Leishmania and application to the study of drug targets and resistance mechanisms", Molecular & Cellular Proteomics, vol. 2, no. 3, pp. 146-155, 2003.
99. P. Cuervo, J. B. De Jesus, M. Junqueira et al., "Proteome analysis of Leishmania (Viannia) braziliensis by two-dimensional gel electrophoresis and mass spectrometry", Molecular and Biochemical Parasitology, vol. 154, no. 1, pp. 6-21, 2007.
100. M. M. Costa, H. M. Andrade, D. C. Bartholomeu et al., "Analysis of Leishmania chagasi by 2-D difference gel eletrophoresis (2-D DIGE) and immunoproteomic: identification of novel candidate antigens for diagnostic tests and vaccine", Journal of Proteome Research, vol. 10, no. 5, pp. 2172-2184, 2011.
101. E. Handman, "Leishmaniasis: current status of vaccine development", ClinicalMicrobiology Reviews, vol. 14, no. 2, pp. 229-243, 2001.
102. P. Salotra, R. C. Duncan, R. Singh, B. V. Subba Raju, G. Sreenivas, and H. L. Nakhasi, "Upregulation of surface proteins in Leishmania donovani isolated frompatients of post kala-azar dermal leishmaniasis", Microbes and Infection, vol. 8, no. 3, pp. 637-644, 2006.
103. N. Singh, R. Almeida, H. Kothari et al., "Differential gene expression analysis in antimony-unresponsive Indian kala azar (visceral leishmaniasis) clinical isolates by DNA microarray", Parasitology, vol. 134, no. 6, pp. 777-787, 2007.
104. G. Srividya, R. Duncan, P. Sharma, B. V. S. Raju, H. L. Nakhasi, and P. Salotra, "Transcriptome analysis during the process of in vitro differentiation of Leishmania donovani using genomic microarrays", Parasitology, vol. 134, no. 11, pp. 1527-1539, 2007.
105. K. Leifso, G. Cohen-Freue, N. Dogra, A. Murray, and W. R. McMaster, "Genomic and proteomic expression analysis of Leishmania promastigote and amastigote life stages: the Leishmania genome is constitutively expressed", Molecular and Biochemical Parasitology, vol. 152, no. 1, pp. 35-46, 2007.
106. J. L. Siqueira-Neto, S. Moon, J. Jang et al., "An image-based highcontent screening assay for compounds targeting intracellular Leishmania donovani amastigotes in human macrophages", PLoS Neglected Tropical Diseases, vol. 6, no. 6, Article ID e1671, 2012.
107. K. El Fadili, N. Messier, P. Leprohon et al., "Role of the ABC transporter MRPA (PGPA) in antimony resistance in Leishmania infantum axenic and intracellular amastigotes", Antimicrobial Agents and Chemotherapy, vol. 49, no. 5, pp. 1988-1993, 2005.
108. A. Mukherjee, P. K. Padmanabhan, S. Singh et al., "Role of ABC transporter MRPA, γ-glutamylcysteine synthetase and ornithine decarboxylase in natural antimony-resistant isolates of Leishmania donovani", Journal of Antimicrobial Chemotherapy, vol. 59, no. 2, pp. 204-211, 2007.
109. B. Vergnes, B. Gourbal, I. Girard, S. Sundar, J. Drummelsmith, and M. Ouellette, "A proteomics screen implicates HSP83 and a small kinetoplastid calpain-related protein in drug resistance in Leishmania donovani clinical field isolates by modulating drug-induced programmed cell death", Molecular and Cellular Proteomics, vol. 6, no. 1, pp. 88-101, 2007.
110. K. El Fadili, J. Drummelsmith, G. Roy, A. Jardim, and M. Ouellette, "Down regulation of KMP-11 in Leishmania infantum axenic antimony resistant amastigotes as revealed by a proteomic screen", Experimental Parasitology, vol. 123, no. 1, pp. 51-57, 2009.
111. V. Lemos De Souza, J. Ascenção Souza, T. M. Correia Silva, P. Sampaio Tavares Veras, and L. A. Rodrigues De-Freitas, "Different Leishmania species determine distinct profiles of immune and histopathological responses in CBA mice", Microbes and Infection, vol. 2, no. 15, pp. 1807-1815, 2000.
112. I. N. Gomes, A. F. D. C. Calabrich, R. D. S. Tavares, J. Wietzerbin, L. A. R. De Freitas, and P. S. T. Veras, "Differential properties of CBA/J mononuclear phagocytes recovered from an inflammatory site and probed with two different species of Leishmania", Microbes and Infection, vol. 5, no. 4, pp. 251-260, 2003.
113. J. P. B. M. Menezes, T. F. Almeida, A. L. O. A. Petersen et al., "Proteomic analysis reveals differentially expressed proteins in macrophages infected with Leishmania amazonensis or Leishmania major", Microbes and Infection, vol. 15, no. 8-9, pp. 579-591, 2013.
114. L. Neckers and U. Tatu, "Molecular chaperones in pathogen virulence: emerging new targets for therapy", Cell Host and Microbe, vol. 4, no. 6, pp. 519-527, 2008.
115. R. S. Gupta, "Phylogenetic analysis of the 90 kDheat shock family of protein sequences and an examination of the relationship among animals, plants, and fungi species", Molecular Biology and Evolution, vol. 12, no. 6, pp. 1063-1073, 1995.
116. B. Chen, D. Zhong, and A. Monteiro, "Comparative genomics and evolution of the HSP90 family of genes across all kingdoms of organisms", BMC Genomics, vol. 7, Article 156, 2006.
117. B. T. Lai, N. W. Chin, A. E. Stanek, W. Keh, and K. W. Lanks, "Quantitation and intracellular localization of the 85K heat shock protein by using monoclonal and polyclonal antibodies", Molecular and Cellular Biology, vol. 4, no. 12, pp. 2802-2810, 1984.
118. E. A. A. Nollen and R. I. Morimoto, "Chaperoning signaling pathways: molecular chaperones as stress-sensing 'heat shock' proteins", Journal of Cell Science, vol. 115, no. 14, pp. 2809-2816, 2002.
119. D. J. Klionsky, F. C. Abdalla, H. Abeliovich et al., "Guidelines for the use and interpretation of assays for monitoring autophagy", Autophagy, vol. 8, no. 4, pp. 445-544, 2012.
120. W. Li, D. Sahu, and F. Tsen, "Secreted heat shock protein-90 (Hsp90) in wound healing and cancer", Biochimica et Biophysica Acta-Molecular Cell Research, vol. 1823, no. 3, pp. 730-741, 2012.
121. L. Whitesell, E. G. Mimnaugh, B. De Costa, C. E. Myers, and L. M. Neckers, "Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation", Proceedings of the National Academy of Sciences of the United States of America, vol. 91, no. 18, pp. 8324-8328, 1994.
122. C. Prodromou, S. M. Roe, R. O'Brien, J. E. Ladbury, P. W. Piper, and L. H. Pearl, "Identification and structural characterization of the ATP/ADP-binding site in the Hsp90 molecular chaperone", Cell, vol. 90, no. 1, pp. 65-75, 1997.
123. J. S. Isaacs, W. Xu, and L. Neckers, "Heat shock protein 90 as a molecular target for cancer therapeutics", Cancer Cell, vol. 3, no. 3, pp. 213-217, 2003.
124. K. Jhaveri, T. Taldone, S. Modi, and G. Chiosis, "Advances in the clinical development of heat shock protein 90 (Hsp90) inhibitors in cancers", Biochimica et Biophysica Acta-Molecular Cell Research, vol. 1823, no. 3, pp. 742-755, 2012.
125. H.-J. Ahn, S. Kim, and H.-W. Nam, "Molecular cloning of the 82-kDa heat shock protein (HSP90) of Toxoplasma gondii associated with the entry into and growth in host cells", Biochemical and Biophysical Research Communications, vol. 311, no. 3, pp. 654-659, 2003.
126. G. Banumathy, V. Singh, S. R. Pavithra, and U. Tatu, "Heat shock protein 90 function is essential for Plasmodium falciparumgrowth in human erythrocytes", The Journal of Biological Chemistry, vol. 278, no. 20, pp. 18336-18345, 2003.
127. R. Kumar, A. Musiyenko, and S. Barik, "Plasmodium falciparum calcineurin and its association with heat shock protein 90: mechanisms for the antimalarial activity of cyclosporin A and synergism with geldanamycin", Molecular and Biochemical Parasitology, vol. 141, no. 1, pp. 29-37, 2005.
128. R. Pallavi, N. Roy, R. K. Nageshan et al., "Heat shock protein 90 as a drug target against protozoan infections: biochemical characterization of HSP90 from plasmodium falciparum and Trypanosoma evansi and evaluation of its inhibitor as a candidate drug", Journal of Biological Chemistry, vol. 285, no. 49, pp. 37964-37975, 2010.
129. W. B. Pratt and D. O. Toft, "Regulation of signaling protein function and trafficking by the hsp90/hsp70-based chaperone machinery", Experimental Biology and Medicine, vol. 228, no. 2, pp. 111-133, 2003.
130. A. G. Erlejman, M. Lagadari, J. Toneatto, G. Piwien-Pilipuk, and M. D. Galigniana, "Regulatory role of the 90-kDa-heat-shock protein (Hsp90) and associated factors on gene expression", Biochimica et Biophysica Acta, vol. 1839, no. 2, pp. 71-87, 2014.
131. M. Wiesgigl and J. Clos, "Heat shock protein 90 homeostasis controls stage differentiation in Leishmania donovani", Molecular Biology of the Cell, vol. 12, no. 11, pp. 3307-3316, 2001.
132. A. L. D. O. A. Petersen, C. E. S. Guedes, C. L. Versoza et al., "17-AAGkills intracellular Leishmania amazonensis while reducing inflammatory responses in infected macrophages", PLoS ONE, vol. 7, no. 11, Article ID e49496, 2012.
133. D. M. Santos, A. L. Petersen, F. S. Celes et al., "Chemotherapeutic Potential of 17-AAG against Cutaneous Leishmaniasis Caused by Leishmania (Viannia) braziliensis", PLoS Neglected Tropical Diseases, vol. 8, no. 10, Article IDe3275, 2014.
134. J. Alexander and D. G. Russell, "The interaction of leishmania species withmacrophages", Advances in Parasitology, vol. 31, pp. 175-254, 1992.
135. S. Wax, M. Piecyk, B. Maritim, and P. Anderson, "Geldanamycin inhibits the production of inflammatory cytokines in activated macrophages by reducing the stability and translation of cytokine transcripts", Arthritis and Rheumatism, vol. 48, no. 2, pp. 541-550, 2003.
136. A. Chatterjee, C. Dimitropoulou, F. Drakopanayiotakis et al., "Heat shock protein 90 inhibitors prolong survival, attenuate inflammation, and reduce lung injury in murine sepsis", American Journal of Respiratory and Critical Care Medicine, vol. 176, no. 7, pp. 667-675, 2007.
137. V. Poulaki, E. Iliaki, N. Mitsiades et al., "Inhibition of Hsp90 attenuates inflammation in endotoxin-induced uveitis", The FASEB Journal, vol. 21, no. 9, pp. 2113-2123, 2007.
138. B. C. Kone, T. Kuncewicz, W. Zhang, and Z.-Y. Yu, "Protein interactions with nitric oxide synthases: controlling the right time, the right place, and the right amount of nitric oxide", American Journal of Physiology-Renal Physiology, vol. 285, no. 2, pp. F178-F190, 2003.
139. H. Xu, Y. Shi, J. Wang et al., "A heat shock protein 90 binding domain in endothelial nitric-oxide synthase influences enzyme function", Journal of Biological Chemistry, vol. 282, no. 52, pp. 37567-37574, 2007.